Loading...
Loading...
Shares of Akebia Therapeutics
AKBA are rocketing up 48 percent to $25.25 in their first day of trading.
Shares opened at 10:57am EDT on Thursday for $22.90 per share.
The company raised $100.3 million after 5.9 million shares were priced at $17 per share, significantly above the initial range of $14-$17.
Akebia is a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.
Morgan Stanley and Credit Suisse were the lead underwriters for the offering.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in